[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608784":3},{"organization":4,"armGroups":7,"interventions":59,"overallOfficials":104,"centralContacts":108,"locations":115,"responsibleParty":494,"collaborators":103,"id":496,"slug":497,"hasResults":498,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":498,"sex":504,"minAge":505,"maxAge":103,"enrollmentInfo":506,"targetDuration":103,"studyType":509,"phases":510,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":118,"whyStopped":103,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":531},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,15,20,25,29,34,38,44,48,53],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1a: Cohort DL1A","EXPERIMENTAL","Tulmimetostat DL1 QD + JSB462 Dose 1 QD",[13,14],"Drug: Tulmimetostat DL1 QD","Drug: JSB462 Dose 1 QD",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 1a: Cohort DL1B","Tulmimetostat DL1 QD + JSB462 Dose 2 QD",[13,19],"Drug: JSB462 Dose 2 QD",{"label":21,"type":10,"description":22,"interventionNames":23},"Part 1a: Cohort DL2A","Tulmimetostat DL2 QD + JSB462 Dose 1 QD",[24,14],"Drug: Tulmimetostat DL2 QD",{"label":26,"type":10,"description":27,"interventionNames":28},"Part 1a: Cohort DL2B","Tulmimetostat DL2 QD + JSB462 Dose 2 QD",[24,19],{"label":30,"type":10,"description":31,"interventionNames":32},"Part 1a: Cohort DL3A","Tulmimetostat DL3 QD + JSB462 Dose 1 QD",[33,14],"Drug: Tulmimetostat DL3 QD",{"label":35,"type":10,"description":36,"interventionNames":37},"Part 1a: Cohort DL3B","Tulmimetostat DL3 QD + JSB462 Dose 2 QD",[33,19],{"label":39,"type":10,"description":40,"interventionNames":41},"Part 1b : Arm A","Tulmimetostat Dose 1 QD + JSB462 QD",[42,43],"Drug: Tulmimetostat Doses 1 or 2 QD","Drug: JSB462 QD",{"label":45,"type":10,"description":46,"interventionNames":47},"Part 1b: Arm B","Tulmimetostat Dose 2 QD + JSB462 QD",[42,43],{"label":49,"type":10,"description":50,"interventionNames":51},"Part 2: Arm 1","Tulmimetostat RP2D QD + JSB462 QD",[52,43],"Drug: Tulmimetostat RP2D QD",{"label":54,"type":55,"description":56,"interventionNames":57},"Part 2: Arm 2","ACTIVE_COMPARATOR","Standard of Care at the discretion of the investigator",[58],"Drug: Standard of Care (SoC)",[60,67,71,75,80,85,90,94,99],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":65},"DRUG","Tulmimetostat DL1 QD","Part 1a (dose escalation):\n\nDoses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))",[9,16],[66],"DZR123",{"type":61,"name":68,"description":63,"armGroupLabels":69,"otherNames":70},"Tulmimetostat DL2 QD",[21,26],[66],{"type":61,"name":72,"description":63,"armGroupLabels":73,"otherNames":74},"Tulmimetostat DL3 QD",[30,35],[66],{"type":61,"name":76,"description":77,"armGroupLabels":78,"otherNames":79},"Tulmimetostat Doses 1 or 2 QD","Part 1b (dose expansion and optimization):\n\ntulmimetostat doses 1 or 2 QD",[39,45],[66],{"type":61,"name":81,"description":82,"armGroupLabels":83,"otherNames":84},"Tulmimetostat RP2D QD","Part 2:\n\ntulmimetostat Recommended Phase 2 Dose (RP2D) QD",[49],[66],{"type":61,"name":86,"description":86,"armGroupLabels":87,"otherNames":88},"JSB462 Dose 1 QD",[9,21,30],[89],"luxdegalutamide",{"type":61,"name":91,"description":91,"armGroupLabels":92,"otherNames":93},"JSB462 Dose 2 QD",[16,26,35],[89],{"type":61,"name":95,"description":96,"armGroupLabels":97,"otherNames":98},"JSB462 QD","The dose of JSB462 QD will be determined based on the totality of data from Part 1a",[39,45,49],[89],{"type":61,"name":100,"description":101,"armGroupLabels":102,"otherNames":103},"Standard of Care (SoC)","Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator",[54],null,[105],{"name":106,"affiliation":106,"role":107},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[109,113],{"name":106,"role":110,"phone":111,"phoneExt":103,"email":112},"CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":106,"role":110,"phone":114,"phoneExt":103,"email":112},"+41613241111",[116,138,154,171,187,203,219,236,253,265,274,282,293,303,313,321,329,339,347,352,363,372,383,392,401,412,423,433,442,447,453,462,470,475,486],{"facility":117,"status":118,"city":119,"state":120,"zip":121,"country":122,"countryCode":123,"cosmosGeoPoint":124,"geoPoint":129,"contacts":130},"Sarah Cannon Research Institute","RECRUITING","Denver","Colorado","80218","United States","US",{"type":125,"coordinates":126},"Point",[127,128],-104.9847,39.73915,{"lat":128,"lon":127},[131,135],{"name":132,"role":110,"phone":133,"phoneExt":103,"email":134},"Alissa Snow","720-754-2610","alissa.snow@sarahcannon.com",{"name":136,"role":137,"phone":103,"phoneExt":103,"email":103},"Gerald Falchook","PRINCIPAL_INVESTIGATOR",{"facility":117,"status":118,"city":139,"state":140,"zip":141,"country":122,"countryCode":123,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Jacksonville","Florida","32256",{"type":125,"coordinates":143},[144,145],-81.65565,30.33218,{"lat":145,"lon":144},[148,152],{"name":149,"role":110,"phone":150,"phoneExt":103,"email":151},"Kandyce Trejo","941-377-9993","kandyce.trejo@flcancer.org",{"name":153,"role":137,"phone":103,"phoneExt":103,"email":103},"Manish Patel",{"facility":155,"status":118,"city":156,"state":157,"zip":158,"country":122,"countryCode":123,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Emory University","Atlanta","Georgia","30329",{"type":125,"coordinates":160},[161,162],-84.38798,33.749,{"lat":162,"lon":161},[165,169],{"name":166,"role":110,"phone":167,"phoneExt":103,"email":168},"Wilena Session","404-778-1900","wsessio@emory.edu",{"name":170,"role":137,"phone":103,"phoneExt":103,"email":103},"Jacqueline Brown",{"facility":172,"status":118,"city":173,"state":174,"zip":175,"country":122,"countryCode":123,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Wichita Urology Group PA","Wichita","Kansas","67226",{"type":125,"coordinates":177},[178,179],-97.33754,37.69224,{"lat":179,"lon":178},[182,185],{"name":183,"role":110,"phone":103,"phoneExt":103,"email":184},"Tyler Gentry","tgentry@wichitaurology.com",{"name":186,"role":137,"phone":103,"phoneExt":103,"email":103},"Timothy Richardson",{"facility":188,"status":118,"city":189,"state":190,"zip":191,"country":122,"countryCode":123,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Mass General Hospital","Boston","Massachusetts","02114",{"type":125,"coordinates":193},[194,195],-71.05977,42.35843,{"lat":195,"lon":194},[198,201],{"name":199,"role":110,"phone":103,"phoneExt":103,"email":200},"Manda Ngin","mngin@mgh.harvard.edu",{"name":202,"role":137,"phone":103,"phoneExt":103,"email":103},"Xin Gao",{"facility":204,"status":118,"city":205,"state":206,"zip":207,"country":122,"countryCode":123,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"Duke University Medical Center","Durham","North Carolina","27710",{"type":125,"coordinates":209},[210,211],-78.89862,35.99403,{"lat":211,"lon":210},[214,217],{"name":215,"role":110,"phone":103,"phoneExt":103,"email":216},"Tykeytra Dale","tykeytra.dale@duke.edu",{"name":218,"role":137,"phone":103,"phoneExt":103,"email":103},"Christopher Hoimes",{"facility":220,"status":118,"city":221,"state":222,"zip":223,"country":122,"countryCode":123,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Cleveland Clinic Foundation","Cleveland","Ohio","44195",{"type":125,"coordinates":225},[226,227],-81.69541,41.4995,{"lat":227,"lon":226},[230,234],{"name":231,"role":110,"phone":232,"phoneExt":103,"email":233},"Chandra Taylor","216-444-0441","TAYLORC12@ccf.org",{"name":235,"role":137,"phone":103,"phoneExt":103,"email":103},"Shilpa Gupta",{"facility":237,"status":118,"city":238,"state":239,"zip":240,"country":122,"countryCode":123,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"Fred Hutchinson Cancer Research Center","Seattle","Washington","98109-1024",{"type":125,"coordinates":242},[243,244],-122.33207,47.60621,{"lat":244,"lon":243},[247,251],{"name":248,"role":110,"phone":249,"phoneExt":103,"email":250},"Ashley Gagnon","206-606-7486","agagnon@fredhutch.org",{"name":252,"role":137,"phone":103,"phoneExt":103,"email":103},"Michael Schweizer",{"facility":254,"status":118,"city":255,"state":256,"zip":257,"country":258,"countryCode":259,"cosmosGeoPoint":260,"geoPoint":264,"contacts":103},"Novartis Investigative Site","St Leonards","New South Wales","2065","Australia","AU",{"type":125,"coordinates":261},[262,263],151.19836,-33.82344,{"lat":263,"lon":262},{"facility":254,"status":118,"city":266,"state":267,"zip":268,"country":258,"countryCode":259,"cosmosGeoPoint":269,"geoPoint":273,"contacts":103},"Melbourne","Victoria","3000",{"type":125,"coordinates":270},[271,272],144.96332,-37.814,{"lat":272,"lon":271},{"facility":254,"status":118,"city":275,"state":103,"zip":276,"country":258,"countryCode":259,"cosmosGeoPoint":277,"geoPoint":281,"contacts":103},"Liverpool","2170",{"type":125,"coordinates":278},[279,280],150.92588,-33.91938,{"lat":280,"lon":279},{"facility":254,"status":118,"city":283,"state":284,"zip":285,"country":286,"countryCode":287,"cosmosGeoPoint":288,"geoPoint":292,"contacts":103},"Halifax","Nova Scotia","B3H 2Y9","Canada","CA",{"type":125,"coordinates":289},[290,291],-63.57688,44.64269,{"lat":291,"lon":290},{"facility":254,"status":118,"city":294,"state":103,"zip":295,"country":296,"countryCode":297,"cosmosGeoPoint":298,"geoPoint":302,"contacts":103},"Beijing","100021","China","CN",{"type":125,"coordinates":299},[300,301],116.39723,39.9075,{"lat":301,"lon":300},{"facility":254,"status":118,"city":304,"state":103,"zip":305,"country":306,"countryCode":307,"cosmosGeoPoint":308,"geoPoint":312,"contacts":103},"Herlev","2730","Denmark","DK",{"type":125,"coordinates":309},[310,311],12.43998,55.72366,{"lat":311,"lon":310},{"facility":254,"status":118,"city":314,"state":103,"zip":315,"country":306,"countryCode":307,"cosmosGeoPoint":316,"geoPoint":320,"contacts":103},"Odense C","5000",{"type":125,"coordinates":317},[318,319],10.39538,55.40841,{"lat":319,"lon":318},{"facility":254,"status":118,"city":322,"state":103,"zip":323,"country":306,"countryCode":307,"cosmosGeoPoint":324,"geoPoint":328,"contacts":103},"Vejle","7100",{"type":125,"coordinates":325},[326,327],9.5357,55.70927,{"lat":327,"lon":326},{"facility":254,"status":118,"city":330,"state":103,"zip":331,"country":332,"countryCode":333,"cosmosGeoPoint":334,"geoPoint":338,"contacts":103},"Bordeaux","33076","France","FR",{"type":125,"coordinates":335},[336,337],-0.58046,44.84124,{"lat":337,"lon":336},{"facility":254,"status":118,"city":340,"state":103,"zip":341,"country":332,"countryCode":333,"cosmosGeoPoint":342,"geoPoint":346,"contacts":103},"Paris","75015",{"type":125,"coordinates":343},[344,345],2.3488,48.85341,{"lat":345,"lon":344},{"facility":254,"status":118,"city":340,"state":103,"zip":348,"country":332,"countryCode":333,"cosmosGeoPoint":349,"geoPoint":351,"contacts":103},"75231",{"type":125,"coordinates":350},[344,345],{"lat":345,"lon":344},{"facility":254,"status":118,"city":353,"state":354,"zip":355,"country":356,"countryCode":357,"cosmosGeoPoint":358,"geoPoint":362,"contacts":103},"Düsseldorf","North Rhine-Westphalia","40225","Germany","DE",{"type":125,"coordinates":359},[360,361],6.77927,51.22319,{"lat":361,"lon":360},{"facility":254,"status":118,"city":364,"state":365,"zip":366,"country":356,"countryCode":357,"cosmosGeoPoint":367,"geoPoint":371,"contacts":103},"Jena","Thuringia","07740",{"type":125,"coordinates":368},[369,370],11.5899,50.92878,{"lat":370,"lon":369},{"facility":254,"status":118,"city":373,"state":374,"zip":375,"country":376,"countryCode":377,"cosmosGeoPoint":378,"geoPoint":382,"contacts":103},"Milan","MI","20133","Italy","IT",{"type":125,"coordinates":379},[380,381],12.59836,42.78235,{"lat":381,"lon":380},{"facility":254,"status":118,"city":384,"state":385,"zip":386,"country":376,"countryCode":377,"cosmosGeoPoint":387,"geoPoint":391,"contacts":103},"Padova","PD","35128",{"type":125,"coordinates":388},[389,390],11.14261,44.38225,{"lat":390,"lon":389},{"facility":254,"status":118,"city":393,"state":394,"zip":395,"country":376,"countryCode":377,"cosmosGeoPoint":396,"geoPoint":400,"contacts":103},"Orbassano","TO","10043",{"type":125,"coordinates":397},[398,399],7.53813,45.00547,{"lat":399,"lon":398},{"facility":254,"status":118,"city":402,"state":403,"zip":404,"country":405,"countryCode":406,"cosmosGeoPoint":407,"geoPoint":411,"contacts":103},"Kuching","Sarawak","93586","Malaysia","MY",{"type":125,"coordinates":408},[409,410],110.33333,1.55,{"lat":410,"lon":409},{"facility":254,"status":118,"city":413,"state":414,"zip":415,"country":416,"countryCode":417,"cosmosGeoPoint":418,"geoPoint":422,"contacts":103},"Tlalpan","Mexico City","14050","Mexico","MX",{"type":125,"coordinates":419},[420,421],-99.16206,19.29513,{"lat":421,"lon":420},{"facility":254,"status":118,"city":424,"state":103,"zip":425,"country":426,"countryCode":427,"cosmosGeoPoint":428,"geoPoint":432,"contacts":103},"Poznan","60-192","Poland","PL",{"type":125,"coordinates":429},[430,431],16.92993,52.40692,{"lat":431,"lon":430},{"facility":254,"status":118,"city":434,"state":103,"zip":435,"country":434,"countryCode":436,"cosmosGeoPoint":437,"geoPoint":441,"contacts":103},"Singapore","119074","SG",{"type":125,"coordinates":438},[439,440],103.85007,1.28967,{"lat":440,"lon":439},{"facility":254,"status":118,"city":434,"state":103,"zip":443,"country":434,"countryCode":436,"cosmosGeoPoint":444,"geoPoint":446,"contacts":103},"308433",{"type":125,"coordinates":445},[439,440],{"lat":440,"lon":439},{"facility":254,"status":118,"city":448,"state":449,"zip":450,"country":451,"countryCode":452,"cosmosGeoPoint":103,"geoPoint":103,"contacts":103},"Santiago Compostela","A Coruna","15706","Spain","ES",{"facility":254,"status":118,"city":454,"state":455,"zip":456,"country":451,"countryCode":452,"cosmosGeoPoint":457,"geoPoint":461,"contacts":103},"L'Hospitalet de Llobregat","Barcelona","08907",{"type":125,"coordinates":458},[459,460],2.10028,41.35967,{"lat":460,"lon":459},{"facility":254,"status":118,"city":463,"state":103,"zip":464,"country":451,"countryCode":452,"cosmosGeoPoint":465,"geoPoint":469,"contacts":103},"Madrid","28009",{"type":125,"coordinates":466},[467,468],-3.70256,40.4165,{"lat":468,"lon":467},{"facility":254,"status":118,"city":463,"state":103,"zip":471,"country":451,"countryCode":452,"cosmosGeoPoint":472,"geoPoint":474,"contacts":103},"28041",{"type":125,"coordinates":473},[467,468],{"lat":468,"lon":467},{"facility":254,"status":118,"city":476,"state":477,"zip":478,"country":479,"countryCode":480,"cosmosGeoPoint":481,"geoPoint":485,"contacts":103},"Sutton","Surrey","SM2 5PT","United Kingdom","UK",{"type":125,"coordinates":482},[483,484],-0.2,51.35,{"lat":484,"lon":483},{"facility":254,"status":118,"city":487,"state":103,"zip":488,"country":479,"countryCode":480,"cosmosGeoPoint":489,"geoPoint":493,"contacts":103},"London","W1G 6AD",{"type":125,"coordinates":490},[491,492],-0.12574,51.50853,{"lat":492,"lon":491},{"type":495,"investigatorFullName":103,"investigatorTitle":103,"investigatorAffiliation":103,"oldNameTitle":103,"oldOrganization":103},"SPONSOR","100608784","phase-1-an-open-label-dose-escalation-and-expansion-followed-by-a-phase-ii-study-of-tulmimetostat-dzr123-and-jsb462-luxdegalutamide-in-patients-with-progressive-metastatic-castrate-resistant-prostate-cancer-mcrpc-tulmistar-01-100608784",false,"NCT07206056","An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","TulmiSTAR-01","Key Inclusion Criteria:\n\n* Participant is an adult man ≥ 18 years of age.\n* Participant must have histologically and\u002For cytologically confirmed adenocarcinoma of the prostate without neuroendocrine or small cell features (current or prior biopsy of the prostate and\u002For metastatic site).\n* Participant must have ≥ 1 metastatic lesion that is present on screening\u002Fbaseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to start of treatment (Part 1a dose escalation) or randomization (Part 1b dose expansion and Part 2).\n* Participant must have progressive mCRPC.\n* Participant must have a castrate level of serum\u002Fplasma testosterone (\\\u003C 50 ng\u002FdL or \\\u003C 1.7 nmol\u002FL).\n* Prior ARPI therapy:\n\n  * Part 1a and 1b only: must have progressed on at least one prior second generation ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide).\n  * Part 2 only: must have progressed on one prior second generation ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide).\n* Prior chemotherapy:\n\n  * Part 1a dose escalation only: may have received ≤ 2 prior lines of chemotherapy in CRPC setting. Note: Prior chemotherapy is permitted in the HSPC setting.\n  * Part 1b dose expansion\u002Foptimization only: may have received up to one prior line of chemotherapy in CRPC setting. Note: Prior chemotherapy is permitted in the HSPC setting.\n  * Part 2 only: Participants must be taxane-naïve in mCRPC setting; prior chemotherapy permitted in HSPC setting only\n\nKey Exclusion Criteria:\n\n* Previous treatment with any PRC2 inhibitor, including but not limited to EZH2 inhibitors, EZH2\u002F1 inhibitors, or embryonic ectoderm development (EED) inhibitors.\n* Previous treatment with a protein degrader compound that targets the AR.\n* Known hypersensitivity or contraindication to any of the study treatment components or its excipients or to drugs of similar chemical classes.\n* Treatment with any investigational agent within 28 days (or 5 half-lives, whichever is longer) prior to study entry.\n* Previous treatment with radioligand therapy in the mCRPC setting, except in Part 1a where participants may have received RLT in mCRPC setting.\n* Participants with evidence of mCRPC or biochemical recurrence \u002F PSA only disease or asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy and with normal PSA for ≥ 1 year prior to study entry.\n* Participants with a history of CNS metastases must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable, asymptomatic, and not receiving corticosteroids for the purpose of maintaining neurologic integrity. Those with leptomeningeal disease are eligible if those areas have been treated, are stable, and no neurological impairment is present. For those with parenchymal CNS metastasis (or a history of CNS metastasis), baseline and subsequent radiological imaging must include evaluation of the brain with MRI (preferred) or CT with contrast.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","MALE","18 Years",{"count":507,"type":508},188,"ESTIMATED","INTERVENTIONAL",[511,512],"PHASE1","PHASE2","This is a two-part, Phase I\u002FII, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).",[515],"Progressive Metastatic Castrate Resistant Prostate Cancer",[517,518,519,520,521,502],"metastatic castrate resistant prostate cancer (mCRPC)","tulmimetostat (DZR123)","luxdegalutamide (JSB462)","Androgen Deprivation Therapy (ADT)","Standard of care (SoC)","2026-08-20",{"date":524,"type":525},"2026-08-21","ACTUAL",{"date":527,"type":525},"2025-10-15",{"date":529,"type":508},"2030-12-01",{"name":106,"class":6},35]